《亞洲股市》日經半日續跌163點 藥廠第一三共逆市飆12.9%
日經繼上日收挫611點或1.9%後,今早(20日)續跌最多336點或1.1%,曾低見31,093;半日收跌163點或0.5%,報31,266。美元兌日圓報149.84。
主要銀行股續軟,三菱日聯、瑞穗微跌0.4%至0.5%、Resona控股、三井住友各跌1.3%。
權重股拖低大市,東電、松下、軟銀、資生堂及三菱化學各跌約2%至3%、蘋果供應商太陽誘電挫4%。主要車股續弱勢,本田、三菱汽車微跌0.5%至0.6%、豐田、日產各跌1.1%。
藥廠第一三共盤中曾飆17.6%,半日收漲12.9%,公司宣布與默沙東(Merck)(MRK.US)達成價值最多220億美元合作協議,開發及商業化第一三共三款抗體藥物複合體(ADC)候選藥以治療癌症。默沙東將向第一三共支付40億美元預付款,未來兩年再支付15億美元;按未來銷售里程碑,默沙東或再支付最多165億美元予第一三共。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.